Badalona-barcelone, Spain

INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

NCT03745638 For more information, please contact Incyte Corporation at 1.855.463.3463

TemPo Studies

**All eligible study participants will receive at no cost:** • Study-related consultation and care • Study visits, tests, assessments, and procedures • Study drugs (investigational drug or placebo)

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

This is a two-part, Phase 2, double-blind, placebo-controlled, randomized, multicentre study. Subjects with a diagnosis of PD and dyskinesias in PD will complete a Screening Visit to assess eligibility to participate in the study.

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema

We are currently recruiting participants for the BLUEPRINT study. This study investigates the effectiveness, safety, and tolerability of the drug BLU-5937 for chronic itch in people with eczema.

For more information and to register to the study, please visit the study page: **<https://innovaderm.com/studies/blueprint-study-atopic-dermatitis/>**

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation